Lymphangioleiomyomatosis (LAM) is a progressive lung disease that primarily affects young women. Genetic evidence suggests that LAM cells bearing TSC2 mutations migrate to the lungs, proliferate, and cause cystic remodeling. The female predominance indicates that estrogen plays a critical role in LAM pathogenesis, and we have proposed that estrogen promotes LAM cell metastasis by inhibition of anoikis. We report here that estrogen increased LAM patient–derived cells’ resistance to anoikis in vitro, accompanied by decreased accumulation of the proapoptotic protein Bim, an activator of anoikis. The resistance to anoikis was reversed by the proteasome inhibitor, bortezomib. Treatment of LAM patient–derived cells with estrogen plus bortezomib promoted anoikis compared with estrogen alone. Depletion of Bim by siRNA in TSC2-deficient cells resulted in anoikis resistance. Treatment of mice with bortezomib reduced estrogen-promoted lung colonization of TSC2-deficient cells. Importantly, molecular depletion of Bim by siRNA in Tsc2-deficient cells increased lung colonization in a mouse model. Collectively, these data indicate that Bim plays a key role in estrogen-enhanced survival of LAM patient–derived cells under detached conditions that occur with dissemination. Thus, targeting Bim may be a plausible future treatment strategy in patients with LAM.
Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis

Chenggang Li,¹ Na Li,¹ Xiaolei Liu,¹ Erik Y. Zhang,¹ Yang Sun,¹ Kouhei Masuda,¹ Jing Li,³ Julia Sun,¹ Tasha Morrison,¹ Xiangke Li,¹,² Yuanguang Chen,¹,³ Jiang Wang,¹ Nagla A. Karim,⁷ Yi Zhang,⁸ John Blenis,³,⁹ Mauricio J. Reginato,¹⁰ Elizabeth P. Henske,¹¹ and Jane J. Yu¹,²

¹University of Cincinnati College of Medicine, Department of Internal Medicine, Pulmonary, Critical Care and Sleep Medicine, Cincinnati, Ohio, USA. ²The First Affiliated Hospital of Zhengzhou University, Department of Oncology, Zhengzhou, Henan, China. ³Harvard Medical School, Department of Cell Biology, Boston, Massachusetts, USA. ⁴Boston University School of Medicine, Department Molecular and Translational Medicine, Boston, Massachusetts, USA. ⁵The First Affiliated Hospital of Guangzhou Medical University, Department of Gastrointestinal Surgery, Guangzhou, China. ⁶University of Cincinnati College of Medicine, Department of Pathology and Lab Medicine, Cincinnati, OH, USA. ⁷University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Hematology and Oncology, Cincinnati, Ohio, USA. ⁸The First Affiliated Hospital of Zhengzhou University, Biotherapy Center and Department of Oncology, Zhengzhou, Henan, China. ⁹Weill Cornell Medicine Sandra and Edward Meyer Cancer Center, New York, New York, USA. ¹⁰Drexel University College of Medicine, Department of Biochemistry and Molecular Biology, Philadelphia, Pennsylvania, USA. ¹¹Brigham and Women's Hospital-Harvard Medical School, Boston, Massachusetts, USA.

Introduction

Lymphangioleiomyomatosis (LAM) is a progressive lung disease that primarily affects young women. Genetic evidence suggests that LAM cells bearing TSC2 mutations migrate to the lungs, proliferate, and cause cystic remodeling. The female predominance indicates that estrogen plays a critical role in LAM pathogenesis, and we have proposed that estrogen promotes LAM cell metastasis by inhibition of anoikis. We report here that estrogen increased LAM patient-derived cells’ resistance to anoikis in vitro, accompanied by decreased accumulation of the proapoptotic protein Bim, an activator of anoikis. The resistance to anoikis was reversed by the proteasome inhibitor, bortezomib. Treatment of LAM patient-derived cells with estrogen plus bortezomib promoted anoikis compared with estrogen alone. Depletion of Bim by siRNA in TSC2-deficient cells resulted in anoikis resistance. Treatment of mice with bortezomib reduced estrogen-promoted lung colonization of TSC2-deficient cells. Importantly, molecular depletion of Bim by siRNA in Tsc2-deficient cells increased lung colonization in a mouse model. Collectively, these data indicate that Bim plays a key role in estrogen-enhanced survival of LAM patient-derived cells under detached conditions that occur with dissemination. Thus, targeting Bim may be a plausible future treatment strategy in patients with LAM.

Conflict of interest: The authors declare that no conflict of interest exists.

Submitted: January 20, 2016
Accepted: October 10, 2016
Published: November 17, 2016

Reference information:
JCI Insight. 2016;1(19):e86629. doi:10.1172/jci.insight.86629.

Lymphangioleiomyomatosis (LAM) is a progressive lung disease that primarily affects young women. Genetic evidence suggests that LAM cells bearing TSC2 mutations migrate to the lungs, proliferate, and cause cystic remodeling. The female predominance indicates that estrogen plays a critical role in LAM pathogenesis, and we have proposed that estrogen promotes LAM cell metastasis by inhibition of anoikis. We report here that estrogen increased LAM patient-derived cells’ resistance to anoikis in vitro, accompanied by decreased accumulation of the proapoptotic protein Bim, an activator of anoikis. The resistance to anoikis was reversed by the proteasome inhibitor, bortezomib. Treatment of LAM patient-derived cells with estrogen plus bortezomib promoted anoikis compared with estrogen alone. Depletion of Bim by siRNA in TSC2-deficient cells resulted in anoikis resistance. Treatment of mice with bortezomib reduced estrogen-promoted lung colonization of TSC2-deficient cells. Importantly, molecular depletion of Bim by siRNA in Tsc2-deficient cells increased lung colonization in a mouse model. Collectively, these data indicate that Bim plays a key role in estrogen-enhanced survival of LAM patient-derived cells under detached conditions that occur with dissemination. Thus, targeting Bim may be a plausible future treatment strategy in patients with LAM.

Introduction

Lymphangioleiomyomatosis (LAM) is a devastating disease affecting young women. The proposed pathogenesis of LAM holds that histologically benign-appearing smooth muscle cells arise from an unknown source and metastasize to the lungs, where they promote destructive cystic remodeling. About 30%–40% of women with tuberous sclerosis complex (TSC), a genetic disorder caused by TSC1 and TSC2 gene defects, have radiographic evidence of LAM (1, 2). A Mayo Clinic study of a series of TSC patients reported that LAM was one of the leading causes of death in women with TSC (3). LAM also occurs in a sporadic form (S-LAM) in women who do not have TSC. In those patients, somatic TSC2 mutations have been reported in lesional cells from the lung, kidney, and lymphatics, but not in normal tissues from those organs or in circulating myeloid cells (4). Multiple preclinical studies demonstrated the effectiveness of rapamycin, an mTORC1 inhibitor, in animal models of TSC (5), which led to rapid clinical translation, and demonstration that rapamycin has clinical benefit in patients with LAM (6). In patients with end-stage LAM, lung transplantation is offered as a last resort, although recurrence of LAM has been reported in the donor allograft (7).
The reasons that LAM exclusively affects women remain unclear. The remarkable female predominance of LAM suggests that female hormones, including estrogen, may contribute to disease pathogenesis. Both LAM cells and angiomyolipoma cells express estrogen receptor α, estrogen receptor β, and the progesterone receptor (8). We have previously discovered that estrogen promotes the survival and lung colonization of intravenously injected Tsc2-deficient rat-uterine leiomyoma-derived ELT3 cells in our preclinical mouse model of LAM (9). In a similar xenograft tumor model, estrogen strongly enhanced the pulmonary metastasis of ELT3 cells, associated with an increase in MEK1/2-Erk1/2 signaling in circulating tumor cells. Collectively, our data indicate that estrogen plays a key role in promoting the survival of disseminated TSC2-deficient LAM-derived cells during disease progression (9), although the precise mechanisms involved have remained elusive.

LAM has been described as a destructive, low-grade metastasizing neoplasm (10). Cells carrying TSC2 mutations have been identified in body fluids including blood, chylous effusions, and urine from women with LAM (11). Tumor cells become metastatic by dissociation from primary sites, survival in the vascular system, and proliferation in distal organs. Cells normally undergo anoikis (anchorage-dependent programmed cell death) after losing contact with extracellular matrix or neighboring cells. As a neoplastic strategy, tumor cells acquire resistance to anoikis to allow survival after detachment from the primary site and dissemination via lymphatic or vascular channels. Tumor cells can acquire resistance to anoikis through genetic mutations that lead to inactivation of the death receptor pathway of caspase activation or overexpression of antiapoptotic proteins, including Bcl-2 family members that contain the Bcl-2 homology (BH) domain 3 (11–13). The Bcl-2-interacting mediator of cell death (Bim), a BH3-only protein, is a critical activator of anoikis. In healthy cells, Bim is inactivated by its interaction with the cytoskeleton (14–18). Upon activation by apoptotic stimuli, Bim is phosphorylated by Erk1/2. Phosphorylation of Bim also promotes rapid proteasome-mediated degradation that facilitates cell survival (19–21).

In this study, we tested the hypothesis that Bim is a critical mediator of estrogen-supported survival of TSC2-deficient LAM patient-derived cells. We report here that estrogen decreases Bim accumulation and induces resistance of LAM patient-derived cells to anoikis. Furthermore, depletion of Bim by small interfering RNA (siRNA) prevents anoikis in LAM patient-derived cells. Bortezomib treatment restores susceptibility to anoikis in estrogen-treated LAM cells by preventing Bim degradation. In vivo, pharmacological suppression of proteasome activity using bortezomib increases Bim accumulation and reduces estrogen-promoted lung colonization of Tsc2-deficient cells, and molecular depletion of Bim by siRNA resulted in enhanced survival of Tsc2-deficient cells in a mouse model of LAM.

Results

Estrogen-promoted resistance of TSC2-deficient LAM patient-derived cells to anoikis is associated with Erk1/2 and Akt activation in vitro. Previously, we showed that estrogen (E₂) induced the survival of Tsc2-deficient Eker leiomyoma-derived (ELT3) cells in detachment conditions (9). To determine the mechanism responsible for E₂-enhanced resistance of ELT3 cells to anoikis, we analyzed the effects of E₂ and Bim on anoikis. E₂ treatment decreased the population of late apoptotic (annexin V+propidium iodide+ [PI+]) cells compared with that of untreated cells (35.2 ± 1.0 vs. 20.3 ± 0.7) in detachment conditions, as analyzed by flow cytometry (Figure 1A). Similarly, E₂ treatment decreased the population of late apoptotic (annexin V+PI+) cells compared with untreated LAM patient-derived cells (621-101 cells) (22) (45.6 ± 0.1 vs. 4.2 ± 0.3) (Figure 1A), suggesting that TSC2-deficient cells were protected from anoikis by E₂ treatment in detachment conditions. E₂ treatment also decreased the level of Bim protein in detachment conditions by 40% and 60%, within 60 minutes and 120 minutes, respectively (Figure 1B), which was inversely correlated with Bim stability.

Mutation of TSC2 leads to hyperactivation of mTORC1 and dysregulation of PI3K-Akt via feedback inhibition mechanisms (23). The expression of Bim is regulated both transcriptionally and posttranscriptionally by PI3K/Akt and Erk1/2 signaling networks (24). We next assessed the effect of E₂ on the activation of these signaling molecules in TSC2-deficient cells grown in detachment conditions. E₂ treatment resulted in Erk1/2 phosphorylation within 5 minutes that continued up to 30 minutes after treatment, and Akt phosphorylation (Ser473) within 30 minutes that lasted up to 120 minutes after treatment in detached ELT3 cells (Figure 1B), indicating a correlation between E₂-induced Bim downregulation and reactivation of Akt and Erk1/2 in Tsc2-deficient cells grown in detachment. To determine whether Bim expression is related to the biochemical features of TSC2-deficient cells, we compared the protein levels of Bim and S6 activation in detached ELT3...
E2 treatment decreased the levels of Bim protein by 40% and 60%, at 60 minutes and 120 minutes, respectively. Interestingly, S6 phosphorylation was undetectable within the first 5 minutes, and gradually increased between 15 and 60 minutes of E2 stimulation (Figure 1B), representing an inverse correlation between Tsc2 deficiency and Bim expression, in agreement with an earlier report that loss of Tsc2 leads to anoikis resistance and anchorage-independent growth (25).

TSC2-deficient cells exhibit hyperactivation of mTORC1, thus leading to constitutive phosphorylation of S6. We found that S6 phosphorylation was undetectable in Tsc2-deficient ELT3 cells grown in suspension (Figure 1B), indicative of detachment-induced suppression of mTORC1 signaling. Furthermore, E2 treatment of 621-101 cells for 24 hours decreased the protein levels of Bim by 39% relative to control (Figure 1C), and correlated with the increased phosphorylation of Erk1/2 in detachment conditions. Importantly, decreased anoikis was associated with decreased levels of cleaved caspase 3 in E2-treated 621-101 cells compared with control cells (Figure 1C). Next, we examined the rapid effect of E2 on Bim levels in detached 621-101 cells. E2 treatment decreased the levels of Bim protein by 50% and 40% within 15 minutes and 30 minutes, respectively (Figure 1D). Importantly, the E2-promoted reduction of Bim was associated with Erk1/2 activation and PARP cleavage, suggesting that E2 protects LAM patient–derived cells from detachment-promoted apoptosis.

**Bim depletion promotes anoikis resistance of TSC2-deficient cells.** To determine whether Bim is a key mediator of detachment-induced death in Tsc2-deficient ELT3 cells, we knocked down Bim using 2 independent
Bim siRNAs. We found that ELT3 cells transfected with these 2 rat Bim siRNAs exhibited 50% and 52% reduction of the transcript levels of Bim measured by real-time RT-PCR (Figure 2A), and 50% and 20% decrease of the protein levels of Bim, based on densitometry of immunoblots using an anti-Bim antibody, relative to control siRNA treatment (Figure 2B). Next, we compared the levels of cleaved caspase 3 as a marker of cell death. ELT3 cells were transfected with the 2 Bim siRNAs for 24 hours in adherent conditions, collected, and cultured in poly(2-hydroxyethyl methacrylate) (poly-HEMA)–coated plates. Levels of Bim, cleaved caspase 3, and cleaved PARP (rat) were analyzed by immunoblotting; Bim levels were quantified using densitometry, and normalized to β-actin. ELT3 cells transfected with 2 independent rat Bim siRNAs were stained with a BD Annexin V: FITC Apoptosis Detection Kit I. Anoikis was determined by flow cytometry (BD FACSCanto II). Annexin V–PI− indicated cells undergoing anoikis (n = 3). (D) 621-101 cells were transfected with 2 independent human Bim siRNAs or control siRNA for 48 hours. Bim transcript levels were measured using real-time RT-PCR (n = 3). (E) 621-101 cells were transfected with 2 independent human Bim siRNAs or control siRNA for 48 hours, followed by a 24-hour culture in poly-HEMA–coated plates. Levels of Bim, cleaved caspase 3, and cleaved PARP (human) were analyzed by immunoblotting; Bim levels were quantified using densitometry, and normalized to β-actin. (F) 621-101 cells transfected with 2 independent human Bim siRNAs were stained with a BD Annexin V: FITC Apoptosis Detection Kit I. Anoikis was determined by flow cytometry (BD FACSCanto II). Annexin V–PI− indicated cells undergoing anoikis (n = 3). Results are representative of 3 experiments. Statistical analysis performed using a 1-way ANOVA test (Dunnett’s multiple comparisons test comparing Bim siRNA-1, Bim siRNA-2 with siControl). *P < 0.05, **P < 0.01, or ***P < 0.005 was considered significant.

Bim siRNAs. We found that ELT3 cells transfected with these 2 rat Bim siRNAs exhibited 50% and 52% reduction of the transcript levels of Bim measured by real-time RT-PCR (Figure 2A), and 50% and 20% decrease of the protein levels of Bim, based on densitometry of immunoblots using an anti-Bim antibody, relative to control siRNA treatment (Figure 2B). Next, we compared the levels of cleaved caspase 3 as a marker of cell death. ELT3 cells were transfected with the 2 Bim siRNAs for 24 hours in adherent conditions, collected, and cultured in poly(2-hydroxyethyl methacrylate) (poly-HEMA)–coated plates for 24 hours, and then analyzed by immunoblotting. The results show that Bim siRNA–transfected ELT3 cells had lower levels of cleaved caspase 3 compared with cells transfected with control siRNA (Figure 2B), suggesting that Bim is a critical mediator of detachment-triggered death of ELT3 cells. Furthermore, we used flow cytometry to assess the effect of Bim depletion on the survival of ELT3 cells in detachment conditions. The percentage of ELT3 cells in late apoptosis (annexin V+PI+) was decreased from 49% to 43%, or from 49% to 33%, after 2 independent Bim knockdowns (Figure 2C), further supporting Bim as a critical mediator of detachment-promoted death of Tsc2-deficient cells.

Next, we depleted Bim using 2 independent human Bim siRNAs in 621-101 cells. Forty-eight hours after siRNA transfection, the transcript levels of Bim were reduced by 41% and 38% (Figure 2D), and protein
levels were decreased by 60% and 40%, relative to control siRNA treatment (Figure 2E). Levels of cleaved PARP and cleaved caspase 3 were markedly decreased in 621-101 cells transfected with the 2 Bim siRNAs compared with control siRNA treatment (Figure 2E). Moreover, the percentage of 621-101 cells in late apoptosis (annexin V+PI+) was decreased from 52% to 20%, or from 52% to 24%, after 2 independent Bim knockdowns (Figure 2F). Collectively, our findings demonstrate that Bim is a critical regulator of detachment-induced apoptosis of TSC2-deficient cells.

Bim mediates E2-promoted cell survival and lung colonization of Tsc2-deficient ELT3 cells in vivo. To investigate the impact of Bim-mediated anoikis on tumor cell survival in a preclinical model of LAM, we intravenously injected female SCID mice with ELT3 luciferase-expressing (ERL4) cells transfected with rat Bim siRNA (number 1) or control siRNA. At 6 hours after cell injection, Bim-depleted cells colonized the lungs more extensively than control siRNA-transfected cells, as indicated by bioluminescence intensity (Figure 3A), although this difference was not statistically significant. Importantly, at 24 hours after cell injection, the control siRNA–transfected cells were barely detectable in the lungs of SCID mice, whereas the Bim-knockdown cells showed a strong and persistent bioluminescence signal. To determine the specificity of Bim depletion in lung colonization, we transfected ERL4 cells with a second Bim siRNA (number 2) or control siRNA, and then injected these cells intravenously into female SCID mice. At 6 hours after cell injection, all mice exhibited enhanced bioluminescence intensity. Importantly, at 24 hours after cell injection, the control siRNA–transfected cells were barely detectable in the lungs of SCID mice, whereas the Bim-knockdown cells showed markedly greater bioluminescence signal relative to the controls (Figure 3B). Quantification of the bioluminescence intensity in mouse lungs showed that ERL4 cells treated with the 2 independent Bim siRNAs exhibited a 5-fold and 6-fold increase in lung colonization relative to control siRNA treatments (Figure 3C). Collectively, these data further support the notion that Bim is a critical regulator of the survival of TSC2-deficient cells.

E2 activates Erk1/2 and increases anoikis resistance of ELT3 and LAM patient–derived cells via Bim degradation in vitro. We have found that Erk1/2 is highly activated by E2 treatment in ELT3 cells and 621-101 cells in vitro (Figure 1) and that E2 treatment leads to increased lung colonization of ELT3-luciferase cells in vivo (7). To investigate the molecular mechanisms of these effects, we examined signaling events underlying the reduced levels of Bim in E2-treated ELT3 cells and 621-101 cells. Flow cytometry analyses showed that E2
Figure 4. Erk1/2 and proteasome inhibition decreases estrogen-promoted cell survival and restores Bim levels in LAM cells. (A) ELT3 cells were seeded in poly-HEMA-coated plates, pretreated with or without 50 μM PD98059, a selective Erk1/2 inhibitor, or 100 nM proteasome inhibitor bortezomib (BTZ), or both PD98059 and BTZ for 15 minutes. The treatments were continued for an additional 24 hours in the presence of 10 nM estrogen (E2) or vehicle control. Cell death was analyzed by flow cytometry (n = 3). (B) The percentage of late apoptotic (annexin V+PI+) cells was determined (n = 3). (C) Immunoblotting analysis shows levels of phospho-Erk1/2, Erk1/2, Bim, and cell death markers cleaved caspase 3 and cleaved PARP in detached ELT3 cells treated with 10 nM E2 with or without 50 μM PD98059, or 100 nM BTZ, or both PD98059 and BTZ. Bim levels were quantified using densitometry, and normalized to β-actin. The lanes were run on the same gel, but were noncontiguous. (D) 621-101 cells were seeded in poly-HEMA-coated plates, pretreated with or without 50 μM PD98059, a selective Erk1/2 inhibitor, or 100 nM BTZ, or both PD98059 and BTZ for 15 minutes. The treatments were continued for an additional 24 hours in the presence of E2 (10 nM) or vehicle control. Cell death was analyzed by flow cytometry (n = 3). (E) The percentage of late apoptotic (annexin V+PI+) cells was determined (n = 3). (F) Immunoblotting analysis shows levels of phospho-Erk1/2, Erk1/2, Bim and cell death markers cleaved caspase 3 and cleaved PARP in detached 621-101 cells treated with 10 nM E2 with or without 50 μM PD98059, or 100 nM BTZ, or both PD98059 and BTZ. Bim levels were quantified using densitometry, and normalized to β-actin (obtained from replicate samples run in parallel). Results are representative of 3 experiments. Statistical analysis performed using a 1-way ANOVA test (Tukey’s multiple comparisons test multiple pairwise comparisons between different groups). *P < 0.05, **P < 0.01, or ***P < 0.005 was considered significant.
treatment decreased the population of detached cells in late apoptosis (annexin V+PI+) by 40% (Figure 4, A and B). We also found that the E2-mediated decrease in the population of cells in apoptosis was partially attenuated by ~45% upon treatment with the Erk1/2 inhibitor PD98059 (Figure 4, A and B). Similarly, PD98059 treatment restored the protein levels of Bim in E2-treated ELT3 cells (Figure 4C). Importantly, cells treated with E2 plus PD98059 exhibited higher levels of cleaved caspase 3 compared with E2 treatment alone (Figure 4C).

Similar findings were observed in detached 621-101 cells (Figure 4, D–F). Together, these data support a role for Bim in mediating E2-protected anoikis via Erk1/2 in TSC2-deficient ELT3 and 621-101 cells.

Bortezomib restores Bim-mediated anoikis of ELT3 and LAM patient–derived cells in vitro. The results above indicate that E2-induced activation of the Erk1/2 pathway contributes to the survival advantage of ELT3 cells and 621-101 cells in detachment conditions. Since Bim is inactivated by proteasome-mediated degradation (26–28), we evaluated the effects of proteasome inhibition on Bim depletion and cell death signaling. We treated detached cells with bortezomib (BTZ) with concurrent E2 stimulation. FACS analysis revealed that BTZ blocked the E2-enhanced survival of ELT3 cells in vitro (Figure 4A). The percentage of cells in late apoptosis (annexin V+PI+) was increased markedly in cells treated with BTZ plus E2 compared with that in cells treated with E2 alone (Figure 4B). Similarly, BTZ treatment restored the protein levels of Bim in E2-treated ELT3 cells (Figure 4C). Importantly, cells treated with E2 plus BTZ exhibited higher levels of cleaved caspase 3 and cleaved PARP compared with E2 treatment alone (Figure 4C). Similar findings were observed in detached 621-101 cells (Figure 4, D–F). Collectively, our data

Figure 5. The proteasome inhibitor bortezomib blocks lung colonization of ELT3 cells in vivo. (A) Simplified study flow. Female ovariectomized SCID mice receiving vehicle control (n = 5) or estrogen (E2) in drinking water were treated with bortezomib (BTZ; 1 mg/kg, dissolved in 100 μl PBS, i.p., n = 5) or control (sterilized PBS, n = 5) 24 hours in advance of cell injection and 6 hours after cell inoculation. Luciferase-expressing ELT3 (ERL4) cells were injected in female SCID mice intravenously; the baseline bioluminescence images were captured immediately, and 6 and 24 hours after cell injection. A second dose of BTZ or control was administered 6 hours after cell injection. (B) Bioluminescence imaging was performed at the indicated times. (C) Bioluminescence intensity (total photon flux) was recorded and quantified. Data are the mean bioluminescence intensities from 5 mice per group. Statistical analysis performed using a 1-way ANOVA test (Tukey’s multiple comparisons test multiple pair-wise comparisons test multiple pair-wise comparisons between different groups). *P < 0.05 or **P < 0.01 was considered significant.
support that Bim mediates E₂-promoted resistance to anoikis in part via proteasome activity that can be targeted by BTZ in TSC2-deficient ELT3 and 621-101 cells in vitro. Of note, BTZ treatment attenuated E₂-protected anoikis to a greater extent in ELT3 (Figure 4, A–C) than that in 621-101 cells (Figure 4, D–F), indicative of tissue specificity. Furthermore, we examined the effect of the combinatorial treatment of BTZ and PD98059 on the survival of ELT3 and 621-101 cells in the presence of E₂ in detachment conditions. ELT3 cells treated with E₂ plus BTZ and PD98059 exhibited higher levels of cleaved caspase 3 and cleaved PARP compared with E₂ treatment alone (Figure 4C). Similar findings were observed in detached 621-101 cells (Figure 4, D–F), indicating that E₂ protects cells from anoikis via multiple mechanisms.

**BTZ reverses E₂-promoted lung colonization of ELT3-luciferase cells in vivo.** To further investigate the role of Bim in the survival of ELT3 cells in vivo, ERL4 cells cultured in detachment conditions were treated with 10 nM E₂ or vehicle control for 24 hours. Cells were resuspended at the same density and intravenously injected into mice pretreated with BTZ 1 day prior to cell inoculation. At the baseline, similar levels of bioluminescence were observed in the chest regions of all mice (Figure 5A). At 6 and 24 hours after cell injection, the bioluminescence in the chest regions of mice inoculated with BTZ-treated cells was decreased by 40% and 70%, respectively, compared with the controls (Figure 5, B and C). These data suggest that Bim plays a critical role in lung colonization by Tsc2-deficient ELT3 cells, in part owing to BTZ’s ability to preserve Bim.

Figure 6. Low Bim accumulation is evident in LAM nodules. Immunofluorescence staining of Bim (green) and smooth muscle actin (SMA) (red) in 2 cases of (A) lung adenocarcinomas and 2 cases of (B) LAM lung tissues. Nuclei were stained with DAPI (blue). Scale bar: 50 μm.
The expression of Bim is low in LAM lung nodule cells. It has been reported that Bim is overexpressed in lung adenocarcinomas relative to normal alveolus (29). We first validated the quality of Bim immunostaining using 2 cases of lung adenocarcinomas. As expected, Bim accumulation was distinct in nodular regions of both lung adenocarcinoma specimens compared with peripheral smooth muscle actin (SMA) immunoreactivity (Figure 6A). We then examined whether our in vitro and in vivo findings of Bim levels were relevant to human LAM. Immunofluorescence staining showed that SMA-positive LAM lesions express lower levels of Bim compared with adjacent lung parenchyma, whereas Bim accumulation is abundant in lung cells (Figure 6B).

Discussion

LAM is a predominantly female lung manifestation characterized by the accumulation of abnormal smooth muscle cells in the lung parenchyma and severe emphysema-like lung destruction that can lead to respiratory failure and mortality (10, 30–32). The marked gender specificity of LAM suggests that circulating female hormones including estrogen promote disease progression. We previously reported that estrogen promoted the survival of tuberin-deficient cells (9). In this study, we identified that Bim is a critical mediator of estrogen-enhanced survival in detachment conditions in LAM patient–derived cells. Importantly, targeting Bim turnover with proteasome inhibitors has a tumor suppression effect in animal models of LAM. Molecular and functional analyses of anoikis resistance of LAM patient–derived TSC2-deficient cells may provide insights into the biology of LAM pathogenesis.

Adhesion to the appropriate extracellular matrix is necessary for normal stromal cells to survive and proliferate, and loss of this adhesion leads to anoikis. Anoikis prevents detached cells from reattaching to an inappropriate site and growing. Acquired resistance to anoikis allows tumor cells to survive and disseminate from the primary tumor site to form a distinct lesion at the distal site. Little is known about the molecular mechanisms underlying E2-induced survival and metastasis of tuberin-deficient cells. The impact of E2 on the growth of tuberin-deficient cells has been reported (9, 33–40). Gu et al. reported that E2 activates Erk1/2 and increases the migration and invasion of tuberin-deficient cells (41). We hypothesize that E2 activates MEK1/2–Erk1/2 pathways to inhibit the accumulation and turnover of the proapoptotic protein Bim, leading to anoikis resistance in tuberin-deficient cells.

In this study, the MEK1/2 inhibitor PD98059, or the proteasome inhibitor BTZ, had a moderate effect on attenuation of E2-enhanced protection from apoptosis in detached TSC2-deficient cells. We also found that PD98059 treatment had limited inhibition of Erk1/2 activation in ELT3 cells and 621-101 cells, although E2-protected anoikis was not drastically attenuated by PD98059 treatment, suggesting that E2 functions through other mechanisms to suppress detachment-induced apoptotic machinery as reported by Frisch and Screaton (42). Moreover, BTZ treatment attenuated E2-protected anoikis to a greater extent in ELT3 than that in 621-101 cells, indicative of tissue specificity (36, 43, 44). Importantly, the combinatorial treatment of PD98059 and BTZ induced more drastic anoikis in E2-treated ELT3 and 621-101 cells, further supporting the notion that E2 protects cells from anoikis via multiple mechanisms.

We previously found that E2 enhances the survival and metastasis of tuberin-deficient cells. In this study, we reinforce the concept that Bim is a key mediator of E2-promoted survival and we identify the signaling events that underlie the enhanced levels of Bim in E2-treated ELT3 cells. As a key BH3 protein regulating anoikis, Bim is regulated both transcriptionally and posttranslationally by the PI3K/Akt and Erk1/2 signaling networks (22). We provide evidence that a modest reduction in Bim expression can substantially increase the survival and metastasis of tuberin-deficient cells in vivo, and the proteasome inhibitor, BTZ, blocks the E2-induced survival of ELT3 cells in vivo (illustrated in Figure 7).

Little is known about the molecular mechanisms underlying LAM pathogenesis. Cells carrying TSC2 mutations have been identified in body fluids including blood, chylous effusions, and urine from
women with LAM (11). We previously found that E2 enhanced the survival of disseminated ELT3 tumor cells and promoted the lung metastasis of ELT3 cells, both of which are associated with E2-induced anoikis resistance (9). LAM has been described as a destructive, low-grade metastasizing neoplasm (10). It is well known that in cancer cells including colon and mammary tumors, anoikis is triggered by detachment from the extracellular matrix and determined by Bim upregulation. Collectively, these findings imply that anoikis resistance may be a common mechanism leading to disease progression for LAM and other malignancies. Our data indicate that Bim accumulation and proteasome activity are critical components facilitating E2-enhanced survival in detachment conditions in LAM patient–derived cells. Thus, targeting Bim-mediated survival pathways including the proteasome may be a plausible future treatment strategy in patients with LAM.

Methods

Cell culture and reagents. ELT3 cells (36, 45) were provided by C. Walker, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas, USA. ERL4 (9) and LAM patient–associated angioymolipoma-derived cells (621-101 cells) were provided by E.P. Henske, Brigham and Women's Hospital-Harvard Medical School (9, 22). Cells were cultured in DMEM/F12 supplemented with 10% FBS, 0.2 μM hydrocortisone, 0.1 nM triiodothyronine, 0.1 μM FeSO4, cholesterol, ITS, 100 ng/ml EGF, 100 μg/ml zeomycin, and 1% penicillin-streptomycin-amphotericin B. 17β-estradiol (E2) (10 nM, Sigma-Aldrich), PD98059 (50 μM, Cell Signaling Technology), and BTZ (100 nM, Velcade) were used as indicated.

Detached cell culture. Cells suspended in serum-free media were seeded onto 6-well plates (BD Falcon) coated with 1.2% poly-HEMA (Sigma-Aldrich, P3932-10G), and treated with indicated reagents.

siRNA transfections. Two independent human Bim siRNAs (50 nM) (Dharmacon, LU-004383-00-0002 and L-004383-00-0005) were transfected into 621-101 cells, and 2 independent rat Bim-siRNAs (50 nM) (Dharmacon, LQ-093533-02-0002 and L-093533-02-0005) were transfected into ELT3 cells and ERL4 cells using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s protocols. Cells were harvested 48 hours after transfection.

Quantitative RT-PCR. RNA from cultured cells was isolated using an RNeasy Mini Kit (Qiagen). Gene expression was quantified using One-Step qRT-PCR Kits (Invitrogen) in the Applied Biosystems Step One Plus Real-Time PCR System, and normalized to β-actin (human) or α-tubulin (rat). Primers used for 621-101 cells and ELT3 cells were: human β-actin forward CACCATTGGCAATGAGCGGTTC and reverse AGGTCTTTGCGGATGTCCACGT; human Bim forward ATCGCCCTGTGGATGACTGAGT and reverse GCCAGGAGAAATCAAACAGAGGC; rat α-tubulin forward GACCTGGAACCCACAGTTATT and reverse ATCTTCCTTGCTGTGATGAG; rat Bim forward ATGGCCAAGCAACCTTCTGA and reverse GCTCCTGTCTTGCGATTATT and reverse ATCTTCCCTTGCTGTGATGAG; rat Bim forward ATGGCCAAGCAACCTTCTGA and reverse GCTCCTGTCTTGCTGTGATGAG; rat Bim forward ATGGCCAAGCAACCTTCTGA and reverse GCTCCTGTCTTGCTGTGATGAG.

Immunoblotting and antibodies. Cells were lysed in m-PER buffer (Pierce). All primary antibodies were diluted in 1× phosphate buffered saline (PBS) supplemented with 0.5% Tween 20 (PBST). Antibodies used were: Bim/BOD (diluted 1:500; ENZO, catalog ADI-AAP-330-E); β-actin (diluted 1:5,000; Sigma-Aldrich, catalog A5441); and the following from Cell Signalling Technology: phospho-Akt (S473) (diluted 1:1,000; catalog 9271); Akt (diluted 1:1,000; catalog 9272); phospho-Erk1/2 (T202/Y204) (diluted 1:2,000; catalog 9101); Erk1/2 (diluted 1:2,000; catalog 9102); phospho-S6 ribosomal protein (Ser235/236) (diluted 1:2,000; catalog 2317); S6 ribosomal protein (diluted 1:2,000; catalog 2317); cleaved caspase 3 (diluted 1:500; catalog 9661); cleaved PARP (human) (diluted 1:500; catalog 9541); cleaved PARP (rat) (diluted 1:500; catalog 9545).

Immunofluorescence staining. Sections were deparaffinized, incubated with anti-Bim (1:100 in PBS + 3% BSA, ENZO, catalog ADI-AAP-330-E) and anti-SMA (1:200 in PBS + 3% BSA, Santa Cruz Biotechnology, catalog sc32251), and secondary antibodies (1:1,000; Invitrogen, catalog A-21202 and A10042). Images were captured with an Olympus BX60 fluorescence microscope.

Fluorescence-activated cell sorting. An Annexin V: FITC Apoptosis Detection Kit I (BD catalog 555547) was used to stain detached ELT3 cells and 621-101 cells according to the manufacturer’s protocols. FACS analysis was carried out on a BD FACSCanto II.

Animal studies. Intact or ovariectomized female C.B_Igh-1b/IcrTac-Prkdcscid (SCID) mice at 4 to 6 weeks of age were purchased from Taconic Biosciences. E2 was dissolved initially in 0.5 ml 95% ethanol (stock concentration, 1 mM), and solubilized E2 was added to the drinking water to produce...
a concentration of 500 nM for oral administration as previously described (46). The water intake was monitored and water bottles were changed twice per week. BTZ (1 mg/kg, dissolved in 100 μl 1× PBS) was administered intraperitoneally (47, 48); the first dose was given 1 day prior to cell inoculation, and the second dose at 6 hours after cell inoculation. Cells (2 × 10^5) were injected into mice intravenously as previously described (9). Animal health was monitored daily during the tumor experiments. All mice were euthanized by carbon dioxide (CO₂) inhalation via compressed gas after the last image was taken.

**Bioluminescent reporter imaging.** Ten minutes prior to imaging, mice were given D-luciferin (120 mg/kg, i.p., PerkinElmer Inc., catalog 122799). Bioluminescent signals were recorded using the Xenogen IVIS Spectrum System. Total photon flux of chest regions was analyzed as previously described (9).

**Statistics.** Data represent the mean ± SEM. Statistical analyses were performed using a 2-tailed Student’s t test when comparing 2 groups for in vitro and in vivo studies, and 1-way ANOVA test (Dunnett’s multiple comparisons test when comparing multiple groups with control group, Tukey’s multiple comparisons test when making multiple pair-wise comparisons between different groups) for multiple group comparison. A P value less than 0.05 was considered significant.

**Study approval.** The University of Cincinnati Standing Committees on Animals approved all procedures described according to standards as set forth in The Guide for the Care and Use of Laboratory Animals. The Institutional Review Board of the University of Cincinnati approved all relevant human studies.

**Author contributions**

CL, NL, XL, JS, TM, KM, YC, MJR, EPH, and JJY designed and performed in vitro studies. JL and JB designed and performed Bim knockdown in vitro experiments. CL and YS designed, performed, and analyzed in vivo experiments. XL and EYZ performed immunofluorescence staining. YZ provided guidance on cell survival experiments. JW and NAK examined lung adenocarcinoma sections. JJY contributed to the study design, implementation, and supervision of the study. CL and JJY wrote the manuscript. All authors had full access to the data, and approved the final version of the manuscript.

**Acknowledgments**

We are grateful to C. Walker (Texas A&M Health Science Center) for providing ELT3 cells. We are also grateful to E. Kopras and F. McCormack for critical reading of the manuscript. J.L. was a Tuberous Sclerosis Alliance Postdoctoral Fellow. J.B. is a LAM Foundation Established Investigator. This study is supported in part by NIH grants HL098216 and DK098331, Department of Defense Exploratory Idea Development Award W81XWH-12-1-0442 (to J.J.Y.), The LAM Foundation Fellowship Award LAM00101F01-14 (to C.L.), and the Lucy J. Engles Fund for TSC and LAM Research (to E.P.H.).

Address correspondence to: Jane J. Yu, University of Cincinnati College of Medicine, Department of Internal Medicine, Pulmonary, Critical Care and Sleep Medicine, 231 Albert Sabin Way-ML 0564, Cincinnati, Ohio 45267, USA. Phone: 513.558.4114; E-mail: yuj9@ucmail.uc.edu.

1. Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc. 2000;75(6):591–594.
2. Franz DN, et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med. 2001;164(4):661–668.
3. Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc. 1991;66(8):792–796.
4. Astrinidis A, et al. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet. 2000;37(1):55–57.
5. Kwiatkowski DJ. Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC). Lymphat Res Biol. 2010;8(1):51–57.
6. McCormack FX, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595–1606.
7. Karbowiczek M, et al. Recurrent lymphangiomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med. 2003;167(7):976–982.
8. Loggimou H, Ao X, Russo I, Henske EP. Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis. Chest. 2000;117(1):25–30.
9. Yu JJ, et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A. 2009;106(8):2635–2640.
10. McCormack FX, Travis WD, Colby TV, Henske EP, Moss J. Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med. 2012;186(12):1210–1212.
45. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C. Rodent model of reproductive tract leiomyomata.

44. Yu J, Astrinidis A, Howard S, Henske EP. Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and

43. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in

42. Frisch SM, Screaton RA. Anoikis mechanisms.

41. Gu X, Yu JJ, Ilter D, Blenis N, Henske EP, Blenis J. Integration of mTOR and estrogen-ERK2 signaling in

40. Sun Y, et al. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1

39. Liu F, et al. Real-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complex. PLoS ONE. 2012;7(6):e38589.

38. Li C, et al. Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis. J Exp Med. 2014;211(1):15–28.

37. Li C, et al. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Clin Invest. 2013;126(11):4978–4994.

36. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C. Rodent model of reproductive tract leiomyomata.

35. Finlay GA, et al. Estrogen-induced smooth muscle cell growth is regulated by tuberin and associated with altered activation of platelet-derived growth factor receptor-beta and ERK-1/2. J Biol Chem. 2004;279(22):23114–23122.

34. Engel D, et al. Estrogen inhibits proliferation and migration of LAM cells in a three-dimensional culture model. Am J Pathol. 2005;167(7):2323–2333.

33. El-Hashemite N, Walker V, Kwiatkowski DJ. Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Cancer Res. 2005;65(6):2474–2481.

32. Taveira-DaSilva AM, Pacheco-Rodriguez G, Moss J. The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. Lymphat Res Biol. 2010;8(1):9–19.

31. Krymskaya VP. Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges. Proc Natl Acad Sci USA. 2004;101(50):17462–17467.

30. Henske EP, McCormack FX. Lymphangioleiomyomatosis - a wolf in sheep's clothing. J Exp Med. 1995;186(6):2063–2073.

29. Sakakibara-Konishi J, et al. Expression of Bim, Noxa, and Puma in non-small cell lung cancer. Cancer Res. 2009;69(2):555–562.

28. Reginato MJ, et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Cell Cycle. 2005;4(3):410–413.

27. Collins NL, Reginato MJ, Paulus JK, Sgroi DC, Labaer J, Brugge JS. G1/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression. Mol Cell Biol. 2005;25(12):5282–5291.

26. Panka DJ, Atkins MB, Mier JW. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Curr Opin Cell Biol. 2001;13(5):555–562.

25. Bulavin DV, et al. Persistent expression of Bim in mouse developing liver results in anemia and anemia-related phenotypes. Mol Cell. 2000;5(3):385–393.

24. Paraiso KH, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cell Death Dis. 2011;2:e1231.

23. Krymskaya VP. Tuberous sclerosis complex: new insights into an old disease. Curr Opin Genet Dev. 2013;23(5):505–511.

22. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol. 2001;13(5):555–562.

21. Panka DJ, Atkins MB, Mier JW. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin Cancer Res. 2000;6(2):712–721.

20. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2000;97(11):6085–6090.

19. Kumasaka T, et al. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol. 2005;29(10):1356–1366.

18. Zhang LN, Li JY, Xu W. A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia. Cancer Gene Ther. 2013;20(1):1–7.

17. Krymskaya VP. Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges. Proc Natl Acad Sci USA. 2004;101(50):17462–17467.

16. Endo Y, et al. Expression of Bim in non-small cell lung cancer. Cancer Res. 2005;65(6):2474–2481.

15. Periyasamy-Thandavan S, et al. Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim. Breast Cancer Res. 2012;14(2):R52.

14. Noda T, Iwai S, Hamada M, Fujita Y, Yura Y. Induction of apoptosis of detached oral squamous cell carcinoma cells by safingol. Possible role of Bim, focal adhesion kinase and endonuclease G. Apoptosis. 2009;14(3):287–297.

13. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2009;16(3):368–377.

12. Akiyama T, Dass CR, Choong PF. Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther. 2009;8(12):3173–3180.

11. Crooks DM, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2004;101(50):17462–17467.

10. Balmanouk K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2009;16(3):368–377.
47. Wagner-Ballon O, et al. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. *Blood*. 2007;110(1):345–353.

48. Sarosiek KA, et al. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. *Proc Natl Acad Sci U S A*. 2010;107(29):13069–13074.